•  home page
  •  location & contact
  • Español
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
Jan 25

EntreChem awarded NEOTEC-2 financing from CDTI

  • 25 January, 2009
  • Financing

The Centre for the Development of Industrial Technology (CDTI) has awarded EntreChem with a NEOTEC-2 grant, consisting on a special loan (a reimbursable loan) of 658.050 EUR for development of new antitumoral molecules. This loan carries a 0% interest rate and its reimbursable anytime contingent to positive cash-flow of the recipient company. For the NEOTEC-2 program, CDTI has thoroughly evaluated the progress of the company line of work regarding new drug development, and given EntreChem strong data, reached the conclusion that further development deserves to be funded under the privileged conditions offered by the NEOTEC program. CDTI only backs projects that are technically and economically viable, but does not demand real guarantees from the promoting company for the awarding of its credit.

About CDTI: The Centre for the Development of Industrial Technology (CDTI) is a Spanish public organisation, under the Ministry of Industry, Commerce and Tourism, whose objective is to help Spanish companies to raise their technological profile. Although CDTI headquarters are located in Madrid, the Centre keeps an strategic network of offices abroad available to Spanish companies to support their international technology activities. For more information, visit www.cdti.es (in Spanish and English).

About EntreChem SL: EntreChem is a start-up company founded as a spin-off of the University of Oviedo in 2005 by Prof. Vicente Gotor, Prof. José A. Salas and Francisco Morís, Ph.D. The company focuses on novel products obtained by biocatalysis and combinatorial biosynthesis approaches, as well as development of processes involving enzymatic catalysis and genetic engineering of metabolic pathways. More information can be found at www.entrechem.com

latest news

  • AI-Therapeutics acquires the preclinical drugs EC-8042 and EC-70124 from EntreChem SL
  • EC-8042 targets SWI/SNF complex vulnerabilities and induces epigenetic reprogramming and permanent cures in rhabdoid tumor
  • EntreChem participates in the ERA-Co-Biotech project «MISSION»

categories

  • Agreements
  • Financing
  • Projects
  • Publications
  • Research
  • Other

archive

EntreChem, S.L.

Vivero Ciencias de la Salud,
c/ Colegio Santo Domingo de Guzmán s/n,
33011 Oviedo, Spain

info@entrechem.com

pipeline  /  chart
· EC-8042
· EC-70124

scientific collaborators
collaborative projects

  • about us
  • technology
  • publications
  • news
Copyright © 2023 EntreChem, S.L. All rights reserved.
  • privacy policy
  • usage policy
  • cookies policy

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview
entrechem

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

You can consult our cookies policy for more information.